$481.81 Million in Sales Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter
Equities research analysts expect that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will announce sales of $481.81 million for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Jazz Pharmaceuticals’ earnings. The lowest sales estimate is $475.55 million and the highest is $485.49 million. Jazz Pharmaceuticals reported sales of $411.86 million during the same quarter last year, which indicates a positive year over year growth rate of 17%. The company is scheduled to report its next earnings report on Tuesday, November 6th.
On average, analysts expect that Jazz Pharmaceuticals will report full-year sales of $1.92 billion for the current year, with estimates ranging from $1.90 billion to $1.93 billion. For the next year, analysts forecast that the firm will report sales of $2.16 billion, with estimates ranging from $2.07 billion to $2.24 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 EPS for the quarter, topping analysts’ consensus estimates of $3.23 by $0.26. The business had revenue of $500.48 million during the quarter, compared to analysts’ expectations of $469.85 million. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%.
In other news, CEO Bruce C. Cozadd sold 1,600 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $173.90, for a total transaction of $278,240.00. Following the completion of the transaction, the chief executive officer now directly owns 282,515 shares in the company, valued at $49,129,358.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Rick E. Winningham sold 16,639 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $176.18, for a total transaction of $2,931,459.02. Following the transaction, the director now owns 15,594 shares of the company’s stock, valued at $2,747,350.92. The disclosure for this sale can be found here. Insiders have sold 34,978 shares of company stock valued at $6,030,128 over the last quarter. Corporate insiders own 3.90% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. bought a new stake in Jazz Pharmaceuticals in the first quarter worth about $192,000. Dimensional Fund Advisors LP raised its position in shares of Jazz Pharmaceuticals by 14.7% in the first quarter. Dimensional Fund Advisors LP now owns 291,850 shares of the specialty pharmaceutical company’s stock valued at $44,066,000 after purchasing an additional 37,486 shares during the period. Russell Investments Group Ltd. raised its position in shares of Jazz Pharmaceuticals by 113.0% in the first quarter. Russell Investments Group Ltd. now owns 32,015 shares of the specialty pharmaceutical company’s stock valued at $4,803,000 after purchasing an additional 16,983 shares during the period. Sei Investments Co. raised its position in shares of Jazz Pharmaceuticals by 75.9% in the first quarter. Sei Investments Co. now owns 9,698 shares of the specialty pharmaceutical company’s stock valued at $1,464,000 after purchasing an additional 4,185 shares during the period. Finally, Stifel Financial Corp raised its position in shares of Jazz Pharmaceuticals by 13.7% in the first quarter. Stifel Financial Corp now owns 20,861 shares of the specialty pharmaceutical company’s stock valued at $3,163,000 after purchasing an additional 2,518 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.
NASDAQ:JAZZ traded down $0.01 during trading hours on Wednesday, reaching $155.99. The company had a trading volume of 417,521 shares, compared to its average volume of 435,077. The company has a current ratio of 3.76, a quick ratio of 3.62 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $9.42 billion, a price-to-earnings ratio of 16.32, a PEG ratio of 0.85 and a beta of 1.04. Jazz Pharmaceuticals has a twelve month low of $128.58 and a twelve month high of $184.00.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Further Reading: Day Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.